Contact us
Mobile menu not yet fully implemented
A hand picked selection of interesting presentations and info
Published on | 1 year ago
Programmes MSCA MSCAThis is a report from the Cluster Event with Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks (ITN) European Industrial Doctorates (EID). On 10 November 2022, the European Commission European Research Executive Agency (REA) organised a cluster event gathering over 160 actors from 75 MSCA ITN EID projects funded under Horizon 2020. The participants represented both the academic and non-academic sectors, which is essential for this mode of MSCA ITN projects.
A key goal of the meeting was to document successes, good practices and lessons learnt, as well as provide recommendations to help improve and enhance the efficiency and impact of the programme for fellows, industry and academia in the future, thus contributing more effectively to the corresponding EU priorities. These conclusions are also applicable to the MSCA Doctoral Networks (DN) Industrial Doctorates (ID) programme in Horizon Europe.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
